---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-001580"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:42:50.128103+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xilio reports 48.2M Series B warrants exercised for $35.8M, cash runway into Q2 2027

## Summary
- 48.2M Series B warrants exercised by Dec 31, 2025, yielding $35.8M gross proceeds; issued 8.2M shares and 40M prefunded warrants.
- As of Jan 2, 2026, 67.5M shares of common stock outstanding.
- 48.2M Series C warrants outstanding at $0.75 strike; if fully exercised could add $36.2M gross.
- Existing cash plus net proceeds from Series B exercise expected to fund operations into Q2 2027.

## SEC filing metadata
- accession: 0001193125-26-001580
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/0001193125-26-001580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526001580/xlo-20260102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-001580
- JSON: https://secwatch.observer/filing/0001193125-26-001580.json
- Plain text: https://secwatch.observer/filing/0001193125-26-001580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.